Published in PLoS One on July 02, 2008
B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol (2012) 1.80
The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS One (2010) 1.32
The evidence for a role of B cells in multiple sclerosis. Neurology (2012) 1.32
High resolution spectral domain optical coherence tomography (SD-OCT) in multiple sclerosis: the first follow up study over two years. PLoS One (2011) 0.98
Biomarkers in Multiple Sclerosis: An Up-to-Date Overview. Mult Scler Int (2013) 0.93
Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases. J Immunol (2014) 0.92
Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis. Respir Res (2012) 0.92
Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers. PLoS One (2013) 0.85
High-quality full-length immunoglobulin profiling with unique molecular barcoding. Nat Protoc (2016) 0.84
Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone. Front Neurol (2013) 0.83
MMP-9 expression is increased in B lymphocytes during multiple sclerosis exacerbation and is regulated by microRNA-320a. J Neuroimmunol (2014) 0.82
Decreased Dicer expression is linked to increased expression of co-stimulatory molecule CD80 on B cells in multiple sclerosis. Mult Scler (2014) 0.81
Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis. Clin Exp Immunol (2013) 0.81
Intrathecal methotrexate treatment in multiple sclerosis. J Neurol (2010) 0.80
Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis. J Neuroinflammation (2015) 0.79
Genetic and infectious profiles influence cerebrospinal fluid IgG abnormality in Japanese multiple sclerosis patients. PLoS One (2014) 0.78
Secondary B cell receptor diversification is necessary for T cell mediated neuro-inflammation during experimental autoimmune encephalomyelitis. PLoS One (2013) 0.77
Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments. Mult Scler Int (2015) 0.77
B-cell populations discriminate between pediatric- and adult-onset multiple sclerosis. Neurol Neuroimmunol Neuroinflamm (2016) 0.76
Street-experienced peripheral B cells traffic to the brain. Sci Transl Med (2014) 0.76
Current Evidence for a Role of the Kynurenine Pathway of Tryptophan Metabolism in Multiple Sclerosis. Front Immunol (2016) 0.76
Brain inflammation is accompanied by peripheral inflammation in Cstb (-/-) mice, a model for progressive myoclonus epilepsy. J Neuroinflammation (2016) 0.75
Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study. PLoS One (2017) 0.75
Elevated Levels of Proinflammatory Cytokines in Cerebrospinal Fluid of Multiple Sclerosis Patients. Front Immunol (2017) 0.75
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med (2008) 12.90
Immunology of multiple sclerosis. Annu Rev Immunol (2005) 9.08
Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med (2006) 6.60
Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain (2005) 5.29
The immunopathology of multiple sclerosis: an overview. Brain Pathol (2007) 4.23
Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain (2007) 3.88
Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol (2004) 3.74
Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol (2006) 3.38
Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol (2005) 2.55
B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol (2006) 2.52
Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol (1996) 2.41
Matrix metalloproteinases and diseases of the CNS. Trends Neurosci (1998) 2.24
Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J Immunol (2003) 2.19
Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain (2005) 2.17
Overlapping roles of CXCL13, interleukin 7 receptor alpha, and CCR7 ligands in lymph node development. J Exp Med (2003) 2.16
Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol (2006) 2.06
B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol (1999) 2.06
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol (2008) 2.02
Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest (1998) 1.95
BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med (2005) 1.92
Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain (2005) 1.92
Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A (2004) 1.91
T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol (1995) 1.78
Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol (2004) 1.71
Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J Immunol (2000) 1.64
Restricted use of VH4 germline segments in an acute multiple sclerosis brain. Ann Neurol (1998) 1.59
Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol (1998) 1.56
Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain (2001) 1.30
Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain (1998) 1.15
Unveiling the enigma of the CNS as a B-cell fostering environment. Trends Immunol (2005) 1.12
The immune response at onset and during recovery from Borrelia burgdorferi meningoradiculitis. Arch Neurol (2003) 1.10
Viral load determines the B-cell response in the cerebrospinal fluid during human immunodeficiency virus infection. Ann Neurol (2007) 1.08
Human B lymphocytes synthesize the 92-kDa gelatinase, matrix metalloproteinase-9. J Biol Chem (1998) 1.08
Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult Scler (2002) 1.04
Expression of matrix metalloproteinases by human plasma cells and B lymphocytes. Eur J Immunol (1998) 1.00
Quantitative estimation of the albumin and gamma globulin in normal and pathologic cerebrospinal fluid by immunochemical methods. Am J Med (1948) 0.98
Accumulation of class switched IgD-IgM- memory B cells in the cerebrospinal fluid during neuroinflammation. J Neuroimmunol (2006) 0.87
Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med (2002) 6.00
Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med (2003) 4.86
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol (2009) 3.91
Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis. Ann Neurol (2014) 3.40
The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol (2013) 3.13
Influences on the reduction of relative telomere length over 10 years in the population-based Bruneck Study: introduction of a well-controlled high-throughput assay. Int J Epidemiol (2009) 2.87
Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol (2005) 2.55
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation (2011) 2.35
Effectiveness of a novel integrative online treatment for depression (Deprexis): randomized controlled trial. J Med Internet Res (2009) 2.34
MYO5B mutations cause microvillus inclusion disease and disrupt epithelial cell polarity. Nat Genet (2008) 2.24
Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res (2008) 2.22
Changes of renal blood flow after ESWL: assessment by ASL MR imaging, contrast enhanced MR imaging, and renal resistive index. Eur J Radiol (2009) 2.02
Cellular aging reflected by leukocyte telomere length predicts advanced atherosclerosis and cardiovascular disease risk. Arterioscler Thromb Vasc Biol (2010) 1.81
Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS One (2010) 1.68
Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychother Psychosom (2014) 1.64
Atrial noninvasive activation mapping of paced rhythm data. J Cardiovasc Electrophysiol (2003) 1.60
Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease. Brain (2013) 1.54
Matrix metalloproteinases and their tissue inhibitors (TIMPs) in Plasmodium falciparum malaria: serum levels of TIMP-1 are associated with disease severity. J Infect Dis (2008) 1.51
Real-time sonoelastography findings in healthy Achilles tendons. AJR Am J Roentgenol (2009) 1.48
Comparison of the specificity of implantable dual chamber defibrillator detection algorithms. Pacing Clin Electrophysiol (2004) 1.46
Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology (2014) 1.45
FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest (2016) 1.45
Long-term results of high vs. normal impedance ventricular leads on actual (Real-Life) pacemaker generator longevity. Europace (2008) 1.45
Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol (2012) 1.43
Clinical predictors of health-related quality of life after pacemaker implantation. Wien Klin Wochenschr (2006) 1.43
Presence of RHD in serologically D-, C/E+ individuals: a European multicenter study. Transfusion (2005) 1.42
Similar qualitative and quantitative changes of mitochondrial respiration following strength and endurance training in normoxia and hypoxia in sedentary humans. Am J Physiol Regul Integr Comp Physiol (2011) 1.38
Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol (2010) 1.37
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol (2010) 1.37
Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am J Pathol (2005) 1.36
Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy. Mov Disord (2007) 1.35
White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: a diffusion-tensor imaging and voxel-based morphometry study. Ann Neurol (2010) 1.34
Role of DNA repair by nonhomologous-end joining in Bacillus subtilis spore resistance to extreme dryness, mono- and polychromatic UV, and ionizing radiation. J Bacteriol (2007) 1.33
EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med (2008) 1.33
Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia. Glia (2012) 1.32
Model-based imaging of cardiac electrical excitation in humans. IEEE Trans Med Imaging (2002) 1.30
[18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro Oncol (2013) 1.30
Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol (2013) 1.27
International quality control survey of neurochemical dementia diagnostics. Neurosci Lett (2006) 1.26
Imaging early practice effects in arithmetic. Neuroimage (2007) 1.26
Retracted Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. Mult Scler Int (2011) 1.26
What makes Internet therapy work? Cogn Behav Ther (2009) 1.25
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler (2013) 1.22
Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis (2009) 1.22
ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology (2010) 1.20
Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients. Mult Scler (2012) 1.19
Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler (2011) 1.19
A widespread distinct pattern of cerebral atrophy in patients with alcohol addiction revealed by voxel-based morphometry. J Neurol Neurosurg Psychiatry (2006) 1.19
A new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis lesions. Brain (2003) 1.18
Sonographic findings in stress fractures of the lower limb: preliminary findings. Eur Radiol (2004) 1.18
Pathogenic T cell responses against aquaporin 4. Acta Neuropathol (2011) 1.16
Endothelial progenitor cells, cardiovascular risk factors, cytokine levels and atherosclerosis--results from a large population-based study. PLoS One (2007) 1.16
HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis (2004) 1.13
Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons. Am J Pathol (2011) 1.13
Immunoglobulin G antibodies to the N-Methyl-D-aspartate receptor are distinct from immunoglobulin A and immunoglobulin M responses. Ann Neurol (2014) 1.13
Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by human dendritic cells and down-regulated following activation. Gene (2004) 1.13
Persistent median artery in the carpal tunnel: color Doppler ultrasonographic findings. J Ultrasound Med (2002) 1.11
Astronaut's organ doses inferred from measurements in a human phantom outside the international space station. Radiat Res (2009) 1.09
A developmental fMRI study of nonsymbolic numerical and spatial processing. Cortex (2007) 1.09
Pattern of brain atrophy in elderly patients with depression revealed by voxel-based morphometry. Psychiatry Res (2008) 1.08
TLR9 cooperates with TLR4 to increase IL-12 release by murine dendritic cells. Mol Immunol (2007) 1.08
Thalamic network oscillations synchronize ontogenetic columns in the newborn rat barrel cortex. Cereb Cortex (2012) 1.07
Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7T MRI. Neurology (2014) 1.07
Multiple sclerosis or multiple possibilities: the continuing problem of misdiagnosis. Neurology (2013) 1.06
Immunogenicity of interferon beta: differences among products. J Neurol (2004) 1.05
Correlation of frataxin content in blood and skeletal muscle endorses frataxin as a biomarker in Friedreich ataxia. Mov Disord (2011) 1.04
Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology (2012) 1.04
Progression of brain atrophy in multiple system atrophy. A longitudinal VBM study. J Neurol (2007) 1.04
Revised McDonald criteria: the persisting importance of cerebrospinal fluid analysis. Ann Neurol (2011) 1.02
Significance of MRI in diagnosis and differential diagnosis of Parkinson's disease. Neurodegener Dis (2010) 1.02
Antibodies as biological markers for pathophysiological processes in MS. J Neuroimmunol (2006) 1.01
Brain capillary endothelial cells proliferate in response to NGF, express NGF receptors and secrete NGF after inflammation. Brain Res (2004) 1.01
Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats. Acta Neuropathol Commun (2013) 1.00
Prognostic value at 5 years of microvascular obstruction after acute myocardial infarction assessed by cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2012) 1.00
Dialysis-related amyloidosis revisited. AJR Am J Roentgenol (2005) 1.00
Temporal dynamics of cerebrospinal fluid anti-aquaporin-4 antibodies in patients with neuromyelitis optica spectrum disorders. J Neuroimmunol (2011) 0.99
Animal models of multiple system atrophy. Trends Neurosci (2005) 0.99
Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases). Clin Immunol (2004) 0.99
HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet (2008) 0.98
Developmental dyscalculia: compensatory mechanisms in left intraparietal regions in response to nonsymbolic magnitudes. Behav Brain Funct (2009) 0.97